When the bourses closed last evening, Amit Bakshi was worth Rs 3,225 crore and Eris Lifesciences, a pharmaceutical company he founded 10 years ago, became a legitimate unicorn. The most profitable, fastest-growing pharma company in five years with the handsomest return on capital employed—the descriptors have been glowing, even as the industry prospects have dimmed of late. The Indian pharma index has been consistently down since 2016, its first decline in five years. And the pall of the US regulatory inspections and warnings hang heavy…
In bad times, a good IPO births a new unicorn
After a long time, Indian pharma is at its lowest ebb, in stocks and sentiments. But Ahmedabad’s Eris Lifesciences beat the odds. Valued at Rs 8070 crore, it’s a pharma company that is making the domestic market look promising once again
Sign up to read this story for free right now
Stories on The Ken are available only for its subscribers. Join us now to get instant access.
Complete access to all stories on The Ken.
Rs. 2,750/year or Rs. 1,200/quarter
All free stories published, past and upcoming
Have an account? Login now